{"id":"W4390990818","doi":"10.1016/j.clml.2024.01.007","title":"Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"Kite Pharma; Genentech; Daiichi Sankyo Europe; Gilead Sciences; Servier; Astellas Pharma; bluebird bio; H. Lundbeck A/S; Syndax Pharmaceuticals; Argenx; Arog Pharmaceuticals; Pharmacyclics; Agios Pharmaceuticals; Loxo Oncology; Astex Pharmaceuticals; Jazz Pharmaceuticals; Pfizer; Incyte; F. Hoffmann-La Roche; Ablynx; AbbVie; Sanofi; GlaxoSmithKline; Amgen; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Venetoclax; Medicine; Internal medicine; Neutropenia; Nausea; Gastroenterology; Febrile neutropenia; Salvage therapy; Mucositis; Oncology; Chemotherapy regimen; Refractory (planetary science); Leukemia; Chemotherapy; Biology; Chronic lymphocytic leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003098217,0.00052898,0.001344812,0.0005666715,0.0001166077,0.000163707,0.0003948741,0.0009530612,0.0003698099],"category_scores_gemma":[0.003292381,0.0004635279,0.0004980579,0.001037337,0.0008733701,0.0002157695,0.000363818,0.001525174,0.0009427743],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.004171704,"about_ca_system_score_gemma":0.007814138,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002084135,"about_ca_topic_score_gemma":0.00002749772,"domain_scores_codex":[0.9942288,0.0005846905,0.001915909,0.001472068,0.0007772151,0.001021329],"domain_scores_gemma":[0.9944993,0.003243285,0.0001690276,0.001011207,0.0001369951,0.0009401773],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.05794533,0.001060439,0.001472281,0.0003463265,0.0002959826,0.006444478,0.0002707826,0.000001851017,0.00127729,0.0009236105,0.02488695,0.9050747],"study_design_scores_gemma":[0.3913003,0.01051936,0.1363236,0.001420558,0.0004173073,0.001039237,0.0002008151,0.01596624,0.00064943,0.001130153,0.4400254,0.001007671],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843901,0.004051561,0.00003602501,0.001271239,0.001434386,0.001674015,0.00004190455,0.0003994425,0.006701274],"genre_scores_gemma":[0.9900376,0.00127325,0.0007416515,0.00130536,0.002410294,0.0002058431,0.00009800118,0.0001666559,0.003761391],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.904067,"threshold_uncertainty_score":0.9998351,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05177241847446667,"score_gpt":0.4032015996761817,"score_spread":0.351429181201715,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}